Hoth’s HT-001 showed 100% response in EGFR therapy toxicity trial. Learn what this means for cancer symptom relief, treatment continuity, and future trials.
PAQ Therapeutics begins Phase 1 trial for PT0511 pan-KRAS degrader and raises $77M. Find out what this means for the future of KRAS-targeted cancer therapy.
Mabwell begins U.S. trial of novel CDH17-targeting ADC 7MW4911 for resistant GI cancers. Learn what makes this payload and target combination clinically unique.
Find out how PhaseV’s AI-powered ClinOps Optimizer is changing IBD trial site selection with causal ML and real-time analytics. Read the full analysis.
A mouse study suggests young microbiota can rejuvenate aging gut tissue. Find out what this could mean for regenerative GI therapies and IBD care.
Legacy’s new AUA-aligned vasectomy platform combines sperm banking and mail-in PVSA—find out how it could reshape male fertility care in the U.S.
Find out how MDLifespan and Cenegenics are redefining plasma exchange for inflammation and toxin removal. Could this reshape preventive health care?
Q Care Plus adds ED, hair loss, and birth control services to its virtual platform. Find out how this reshapes stigma-free access to sexual wellness care.
FAR Biotech brings its QuantumAI platform to Madison. Find out what this move means for drug discovery, platform scalability, and Wisconsin’s biohealth future.
Veloxis earns FDA orphan status for pegrizeprument in liver transplant rejection. Find out what this means for the future of immunosuppressive therapy.